The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata

Journal of Dermatological Treatment

Volumn 23, Issue 6, 2012, Pages 410-420

  Ucak, Haydar ^a   Kandi, Basak ^b   Cicek, Demet ^b   Halisdemir, Nurhan ^b   Dertlioǧlu, Selma Bakar ^c  

^a Elazig Education and Research Hospital   (Turkey)

^b FIRAT UNIVERSITY   (Turkey)

^c HARRAN UNIVERSITY   (Turkey)

Author keywords

alopecia areata; clobetasol propionate; pimecrolimus

Indexed keywords

CLOBETASOL PROPIONATE; PETROLATUM; PIMECROLIMUS;

ADULT; ALOPECIA AREATA; APPLICATION SITE BURNING; ARTICLE; ATOPY; CONTROLLED STUDY; CONVALESCENCE; CORTICOSTEROID THERAPY; CREAM; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLICULITIS; HAIR GROWTH; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCALP; SCORING SYSTEM; TELANGIECTASIA; TREATMENT DURATION;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; ALOPECIA AREATA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; CLOBETASOL; DERMATOLOGIC AGENTS; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PETROLATUM; TACROLIMUS; YOUNG ADULT;

EID: 84869477709     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2011.590788     Document Type: Article

References (20)

1. Dawber RPR, Berker de D. Disorders of hair. In: Rook's Textbook of Dermatology, Disorders of hair. Oxford: Blackwell Scientific Publications;1998. p. 2869-2973.
2. Olsen EA. Hair disorders. Diseases of the skin appendages. In: Fitzpatrick's Dermatology in General Medicine, Disorders of epidermal appendages and related disorders. New York: McGraw-Hill, 1999.p. 729-751.
3. Odom RB, James WD, Berger TG. Andrews' Diseases of the Skin. Philadelphia: WB Saunders; 2000.
4. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part II. Treatment. J Am Acad Dermatol 2010;62:191-202.
5. Bolduc C, Shapiro J. DPCP for the treatment of alopecia areata. Skin Therapy Lett 2000;5:3-4.
6. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000;42:549-566.
7. Hordinsky MK. Medical treatment of noncicatricial alopecia. Semin Cutan Med Surg 2006;25:51-55.
8. Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. National Alopecia Areata Foundation: Alopecia areata investigational assessment guidelinesYPart II. J Am Acad Dermatol 2004;51:440-447.
9. Garg S, Messenger AG. Alopecia areata: evidence-based treatments. Semin Cutan Med Surg 2009;28:15-18.
10. Charuwichitratana S. Randomized double-blind placeboconrolled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch Dermatol 2000;136: 1276-1277.
11. Mancuso G, Balducci A, Casadio C, Farina P, Staffa M, Valenti L, et al. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: A multicenter, prospective, randomized, controlled, investigator-blinded trial. Int J Dermatol 2003;42:572-575. (Pubitemid 36869157)
12. Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: A randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol 2006;20:1243-1247. (Pubitemid 44614622)
13. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi CJ. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Eur Acad Dermatol Venereol 2006;20: 1243-1247. (Pubitemid 44614622)
14. Leyden JL, Kligman AM. Treatment of alopecia areata with steroid solution. Arch Dermatol 1972;106:924.
15. Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneiform response. Dermatologica 1970;141:193-202.
16. Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus Y an antiinflammatory drug targeting the skin. Exp Dermatol 2004;13:721-730. (Pubitemid 39625218)
17. Luger T, Van Leent EJM, Graeber M, Hedgecock S, Thurston M, Kandra A, et al. SDZ ASM 981: An emerging safe and effective treatment of atopic dermatitis. Br J Dermatol 2001;144:788-794. (Pubitemid 32374782)
18. Brownell I, Quan LT, Hsu S. Topical pimecrolimus in the treatmentof seborrheicdermatitis.DermatolOnlineJ2003;9:13.
19. Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 15 pimecrolimus ointment in vitiligo. Eur J Dermatol 2005;15:88-91. (Pubitemid 40434632)
20. Rigopoulos D, Gregoriou S, Korfitis C, Gintzou C, Vergou T, Katrinaki A, Kalogeromitros D. Lack of response of alopecia areata to pimecrolimus cream. Clin Exp Dermatol 2007;32:456-457. (Pubitemid 46828303)